Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
复制标题
DOI：
10.1093/cid/ciaa478
复制
发表时间：
2020-07-31
影响因子：
11.8
通讯作者：
Falck-Ytter, Yngve
中科院分区：
文献类型：
--
作者：
Bhimraj, Adarsh;Morgan, Rebecca L.;Falck-Ytter, Yngve
有许多药物疗法正在使用或考虑用于治疗2019冠状病毒病（COVID-19）。有必要根据对迅速出现的文献的批判性评价，经常更新关于其使用的实践指南。目的是制定循证快速指南，以支持患者、临床医生和其他医疗保健专业人员对COVID-19患者的治疗和管理决策。方法美国传染病学会（IDSA）成立了一个由传染病临床医生、药剂师和方法学家组成的多学科指南小组，他们具有不同领域的专业知识。流程遵循快速建议清单。小组对问题和成果进行了优先排序。然后对同行评议和灰色文献进行系统评价。推荐分级评估、发展和评价（GRADE）方法用于评估证据的确定性并提出建议。结果IDSA指南小组同意了7项治疗建议，并提供了正在进行评估的其他治疗的叙述性摘要。结论小组表达了总体目标，即患者被招募到正在进行的试验中，这将为COVID-19各种疗法的有效性和安全性提供急需的证据，因为我们无法确定大多数治疗方法的益处是否大于危害。
Background There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature. The objective was to develop evidence-based rapid guidelines intended to support patients, clinicians, and other healthcare professionals in their decisions about treatment and management of patients with COVID-19.Methods The Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. Process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and gray literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations.Results The IDSA guideline panel agreed on 7 treatment recommendations and provided narrative summaries of other treatments undergoing evaluations.Conclusions The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much-needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.